Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Clinical Trial ID NCT01844505

PubWeight™ 77.03‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01844505

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
2 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
3 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
4 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
5 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
6 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
7 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
8 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
9 Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013 1.39
10 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
11 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
12 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
13 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
14 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
15 CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2015 1.15
16 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
17 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
18 Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.09
19 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
20 Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 2014 1.06
21 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
22 PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2015 1.02
23 Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2016 1.00
24 Pembrolizumab. J Immunother Cancer 2015 0.99
25 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
26 Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014 0.98
27 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
28 Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015 0.98
29 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol 2015 0.97
30 Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013 0.95
31 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
32 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015 0.92
33 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
34 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
35 Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014 0.86
36 Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 2013 0.85
37 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
38 Increased treatment-related toxicity subsequent to an anti-PD-1 agent. Curr Oncol 2015 0.85
39 Harnessing the immune system to improve cancer therapy. Ann Transl Med 2016 0.83
40 Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep 2014 0.82
41 Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015 0.82
42 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
43 Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology 2015 0.82
44 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
45 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
46 Doubling the blockade for melanoma immunotherapy. Oncoimmunology 2015 0.80
47 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
48 From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma. Nat Rev Clin Oncol 2013 0.79
49 Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother 2014 0.79
50 PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016 0.78
51 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
52 Melanoma immunotherapy. Cancer Biol Ther 2014 0.76
53 Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017 0.75
54 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
55 Intellectual property issues of immune checkpoint inhibitors. MAbs 2015 0.75
56 Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology 2016 0.75
Next 100